Covid 19 Research using Clinical Trials (Home Page)
Report for D018754: Ventricular Dysfunction NIH
(Synonyms: Ventricular Dys, Ventricular Dysfunct, Ventricular Dysfunction)
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (6)
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1068 | Standard of care (SOC) Wiki | 0.71 |
| drug1051 | Standard 12-lead ECG, NT-proBNP, echocardiography Wiki | 0.71 |
| drug93 | Association of diltiazem and niclosamide Wiki | 0.71 |
| drug1180 | Transpulmonary thermodilution Wiki | 0.71 |
| drug393 | Echocardiography Wiki | 0.50 |
| drug505 | Hydroxychloroquine Wiki | 0.08 |
Correlated MeSH Terms (5)
| Name (Synonyms) | Correlation | |
|---|---|---|
| D018487 | Ventricular Dysfunction, Left NIH | 1.00 |
| D012769 | Shock, NIH | 0.35 |
| D055371 | Acute Lung Injury NIH | 0.09 |
| D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.09 |
| D012128 | Respiratory Distress Syndrome, Adult NIH | 0.08 |
Correlated HPO Terms (0)
| Name (Synonyms) | Correlation |
|---|
There are 2 clinical trials
Clinical Trials
1 Hemodynamic Characteristics of Patients With SARS-CoV-2: PiCCOVID Study
The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been declared a public health emergency of international concern. Hospitalized COVID-19-positive patients requiring ICU care is increasing along with the course of epidemic. A large number of these patients developed acute respiratory distress syndrome (ARDS) according to current data. However, the related hemodynamic characteristic has so far been rarely described.
NCT04337983 Coronavirus SARS-CoV-2 COVID-19 Acute Respiratory Distress Syndrome Shock Acute Circulatory Failure Left Ventricular Dysfunction Fluid Overload Device: Transpulmonary thermodilution Device: Echocardiography MeSH:Respiratory Distress Syndrome, Newborn Respiratory Distress Syndrome, Adult Acute Lung Injury Ventricular Dysfunction Ventricular Dysfunction, Left Shock
Primary Outcomes
Description: Body temperature(°C)
Measure: Body temperature Time: Through study completion, an estimation of 6 monthsDescription: Blood pressure in mmHg
Measure: Blood pressure Time: Through study completion, an estimation of 6 monthsDescription: Pulse (heart rate) in times/minute
Measure: Pulse (heart rate) Time: Through study completion, an estimation of 6 monthsDescription: Respiratory rate in times/minute
Measure: Respiratory rate Time: Through study completion, an estimation of 6 monthsDescription: Cardiac index (L/min/m2)
Measure: Data provided by transpulmonary thermodilution-CI Time: Through study completion, an estimation of 6 monthsDescription: Global end-diastolic volume(mL/m2)
Measure: Data provided by transpulmonary thermodilution-GEDV Time: Through study completion, an estimation of 6 monthsDescription: Extravascular lung water (mL/kg)
Measure: Data provided by transpulmonary thermodilution-EVLW Time: Through study completion, an estimation of 6 monthsDescription: Pulmonary vascular permeability index
Measure: Data provided by transpulmonary thermodilution-PVPI Time: Through study completion, an estimation of 6 monthsMeasure: Incidence of abnormal laboratory test results Time: Through study completion, an estimation of 6 months
Secondary Outcomes
Description: Left ventricle ejection fraction, Segmental left ventricle contractility, Speckle tracking data of the left and right ventricles, Dimensions of right and left cavities and Diastolic function of left ventricle
Measure: Incidence of new-onset or reversible systolic left ventricular dysfunction Time: Through study completion, an estimation of 6 monthsDescription: The worst extravascular lung water
Measure: Changes of extravascular lung water measured by transpulmonary thermodilution Time: Change from baseline extravascular lung water at 6 monthsDescription: The worst pulmonary vascular permeability index
Measure: Changes of pulmonary vascular permeability index measured by transpulmonary thermodilution Time: Change from baseline extravascular lung water at 6 monthsMeasure: Correlation between the hemodynamic characteristics and 90-day mortality Time: Up to 90th day after inclusion
2 Opportunistic Screening for Asymptomatic Left Ventricular Dysfunction in COVID-19 Survivors
Coronavirus Disease 2019 (COVID-19) emerged in December 2019, and in mere few months has resulted in a pandemic of viral pneumonia. Substantial proportion of patients with COVID-19 have biochemical evidence of myocardial injuries during the acute phase. Possible mechanisms including acute coronary events, cytokine storm, and COVID-19 related myocarditis, have been postulated for the cardiac involvement in COVID-19. It is uncertain whether COVID-19 survivors are at risk cardiac dysfunction including cardiac arrhythmia and heart failure. The prospective screening study aims to evaluate the possible latent effects from COVID-19 in COVID-19 survivors. COVID-19 survivors 4-6 weeks after hospital discharge will be recruited from the Infectious Disease clinic, Queen Mary Hospital with standard 12-lead electrocardiogram, serum troponin, NT-proBNP, and standard transthoracic echocardiogram. The outcome measures include (1) new onset cardiac arrhythmia, (2) N Terminal (NT)-proBNP elevation above the diagnostic range of heart failure, and (3) newly detected left ventricular dysfunction.
NCT04355884 COVID-19 Diagnostic Test: Standard 12-lead ECG, NT-proBNP, echocardiography MeSH:Ventricular Dysfunction Ventricular Dysfunction, Left
Primary Outcomes
Description: Atrial fibrillation, conduction block
Measure: New-onset cardiac arrhythmia Time: At the time of screeningDescription: Elevated NT-proBNP level above the age-specific diagnostic threshold of heart failure
Measure: Elevation of NT-proBNP Time: At the time of screeningDescription: Left ventricular systolic function
Measure: Left ventricular dysfunction Time: At the time of screening